Table 4.

Demographic and clinical characteristics of subjects who had neurologic deterioration within 24 hrs of treatment initiation

Age/Gender	Tier	Initial SBP, mm Hg	Initial NIHSS Score	Initial GCS Score	Time Interval Between Symptom Onset and Treatment	Cause of Neurologic Deterioration	Time Interval Between Initiation of Treatment and Deterioration	1-mo and 3-mo mRS
55/F	1	250	14	10	2.67 hrs	Hydrocephalus	12 hrs	Lost to follow-up
45/M	2	192	8	15	2.75 hrs	Hematoma expansion	5 mins	1-mo mRS: 4 3-mo mRS: 3
59/F	2	212	10	8	5.25 hrs	Hematoma expansion	15 mins	1-mo mRS: 5 3-mo mRS: 5
74/Ma	3	219	5	15	5.23hrs	Hematoma expansion	14.7 hrs	1-mo mRS: 5 3-mo mRS: 6
43/M	3	181	6	15	2.33 hrs	Hematoma expansion	Before infusion	1-mo mRS: 4 3-mo mRS: 4
82/M	3	183	34	13	3.92 hrs	Hematoma expansion	18.75 hrs	1-mo mRS: 6
46/M	3	228	13	12	5.25 hrs	Hematoma expansion	13.25 hrs	1-mo mRS: 5 3-mo mRS: 4

M, male; F, female; mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale; GCS, Glasgow Coma Scale.

^aAlso had severe adverse events.